Startups
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Overview
Location
United States, California, San Francisco
Employees
11-50
Total raised
$413M
Founded date
2017
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 9, 2021 | Series D round | $150M | |
| Jan 30, 2020 | Series B round | $45M | |
| Aug 1, 2018 | Funding round | $23M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 31, 2020 | Mammoth Biosciences Raises $45M in Series B | SOUTH SAN FRANCISCO, CA, Mammoth Biosciences announced an oversubscribed round of $45 million in its Series B, led by Decheng Capital. >> Click here for more funding data on Mammoth Biosciences >> To export Mammoth Bioscienc... |
| Jan 30, 2020 | Mammoth Biosciences raises $45M Series B round for CRISPR diagnostics, therapeutics development | “As a team on the front lines of discovery in CRISPR, we’ve seen firsthand the need for new tools to deliver on the therapeutic and diagnostic promise that this technology has to offer,” Mammoth CEO Trevor Martin said in a statement. “In po... |
| Jan 30, 2020 | Mammoth Biosciences raises $45M to expand into therapeutics | The company, which uses CRISPR technology to diagnose diseases, will being treating disease as well By now most of us have at least heard of CRISPR, but maybe we don't know what exactly it is. CRISPR, essentially, is a tool that make it eas... |
| Jul 31, 2018 | Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine | Mammoth Biosciences, the biotech company that grew out of a close relationship with CRISPR legend Jennifer Doudna, has raised $23 million in a sturdy Series A. Mammoth previously raised $120,000 from NFX and the company continued quietly pi... |
| Jul 31, 2018 | Mammoth Biosciences raises $23M to democratize diagnostics | The company is a CRISPR-based disease detection platform for at-home use Of all of the ways medicine and healthcare have changed in recent years, one of the most profound has been the increase of at-home testing. So many things that patient... |
| Mammoth Biosciences raises $45M Series B round for CRISPR diagnostics, therapeutics development | A company developing a means of using gene-editing technology to detect disease has raised its latest funding round to continue its diagnostics work. South San Francisco, California-based Mammoth Biosciences said Thursday that it had raised... |
Reviews 0
FAQ about Mammoth Biosciences
When was Mammoth Biosciences founded?
Mammoth Biosciences was founded in 2017.
How much funding has Mammoth Biosciences raised?
Mammoth Biosciences has raised $413M in total across 4 funding rounds.
What funding rounds has Mammoth Biosciences raised?
Parsers VC lists 4 funding rounds of Mammoth Biosciences, among them a Series D round of $150M on Sep 9, 2021, a Series B round of $45M on Jan 30, 2020 and a funding round of $23M on Aug 1, 2018.
What has the press written about Mammoth Biosciences?
Parsers VC has collected 7 articles mentioning Mammoth Biosciences, among them “Mammoth Biosciences Raises $45M in Series B” (Jan 31, 2020) and “Mammoth Biosciences raises $45M Series B round for CRISPR diagnostics, therapeutics development” (Jan 30, 2020).
Is Mammoth Biosciences still active?
Yes, Mammoth Biosciences is active; its latest activity on Parsers VC dates from Sep 9, 2021.